Please Wait.....
Report
Global Bruton's Tyrosine Kinase (BTK) Inhibitors Market Report and Forecast 2023-2031
Market Report I 2023-04-12 I 147 Pages I EMR Inc.
Global Bruton's Tyrosine Kinase (BTK) Inhibitors Market Report and Forecast 2023-2031
Global Bruton's Tyrosine Kinase (BTK) Inhibitors Market Outlook
The growth of the global Bruton's tyrosine kinase (BTK) inhibitors market is driven by the rising number of mantle cell lymphoma cases, which was close to 9.70 billion in 2022. The market value of mantle cell lymphoma is likely to grow at a CAGR of 8.00% in the forecast period of 2023-2031 and is likely to reach 19.39 billion by 2031.
Bruton's Tyrosine Kinase (BTK) Inhibitors Market: Introduction
The global Bruton's Tyrosine Kinase (BTK) inhibitors market report by Expert Market Research provides an in-depth analysis of the market and its segments. BTK inhibitors are targeted therapies that block the BTK enzyme, which is involved in the activation of the B-cell receptor pathway, playing a crucial role in the development and survival of B cells. These inhibitors have shown potential in treating autoimmune diseases and B-cell malignancies, such as chronic lymphocytic leukaemia (CLL) and mantle cell lymphoma (MCL). The report covers the market for BTK inhibitors and provides a detailed analysis of the market size, growth, and trends.
The BTK inhibitors market is expected to witness significant advancements in the coming years, with the development of novel therapies and an increasing focus on personalized medicine driving market growth. Additionally, the expansion of healthcare infrastructure in emerging economies and the increasing demand for advanced diagnostic tools and treatment options are expected to create lucrative opportunities for market players.
Moreover, the growing adoption of telemedicine and digital health technologies may provide new avenues for the management and treatment of B-cell malignancies and autoimmune diseases, potentially improving patient outcomes and reducing healthcare costs. As a result, the global BTK inhibitors market is expected to continue its growth trajectory throughout the forecast period, offering numerous opportunities for key players and investors in the industry.
Bruton's Tyrosine Kinase (BTK) Inhibitors - Application and Usage
Bruton's Tyrosine Kinase (BTK) inhibitors are targeted therapies that play a crucial role in the treatment of various B-cell malignancies and autoimmune diseases. They work by selectively blocking the BTK enzyme, which is involved in the activation of the B-cell receptor pathway, and is essential for the development, survival, and functioning of B cells. The following are the primary applications and usage of BTK inhibitors:
1. B-cell Malignancies: BTK inhibitors have shown significant efficacy in treating B-cell malignancies, such as:
- Chronic Lymphocytic Leukaemia (CLL): CLL is the most common form of adult leukaemia. BTK inhibitors, like ibrutinib, have shown promising results in treating CLL, even in patients with high-risk genetic abnormalities or those who have relapsed or are refractory to other treatments.
- Mantle Cell Lymphoma (MCL): MCL is a rare and aggressive form of non-Hodgkin lymphoma. BTK inhibitors, such as ibrutinib and acalabrutinib, are approved for the treatment of relapsed or refractory MCL.
- Waldenstrom's Macroglobulinemia (WM): WM is a rare, slow-growing type of non-Hodgkin lymphoma. Ibrutinib is approved for the treatment of WM and has demonstrated significant efficacy in patients with relapsed or refractory disease.
- Marginal Zone Lymphoma (MZL): MZL is a slow-growing type of non-Hodgkin lymphoma. BTK inhibitors are being investigated as potential treatments for MZL, particularly in patients who have relapsed or are refractory to other therapies.
2. Autoimmune Diseases: BTK inhibitors have shown potential in treating certain autoimmune diseases, including:
- Rheumatoid Arthritis (RA): BTK plays a role in the activation and survival of B cells involved in the pathogenesis of RA. BTK inhibitors, such as fenebrutinib, are being investigated as potential treatments for RA.
- Systemic Lupus Erythematosus (SLE): SLE is a chronic autoimmune disease that can affect various organs and tissues. BTK inhibitors are being studied for their potential in treating SLE by reducing the production of autoantibodies and inflammatory cytokines.
- Multiple Sclerosis (MS): BTK inhibitors are being explored as potential treatments for MS due to their ability to modulate B cell and immune cell signalling, which can contribute to the pathogenesis of the disease.
Bruton's Tyrosine Kinase (BTK) Inhibitors Market Segmentations
The market can be categorised into type, drug, application, distribution channel, and region.
Market Breakup by Type
- First Generation
- Second Generation
Market Breakup by Drug
- Imbruvica
- Calquence
- Brukinsa
Market Breakup by Application
- Chronic lymphocytic leukemia (CLL)
- Mantle cell lymphoma (MCL)
- Waldenström's Macroglobulinemia
- Small Lymphocytic Lymphoma
- Marginal Zone Lymphoma
- Others
Market Breakup by Distribution Channel
- Hospital Based Pharmacies
- Online Pharmacies
- Retail Pharmacies
- Others
Market Breakup by Region
- North America
- United States of America
- Canada
- Europe
- United Kingdom
- Germany
- France
- Italy
- Others
- Asia Pacific
- China
- Japan
- India
- ASEAN
- Australia
- Others
- Latin America
- Brazil
- Argentina
- Mexico
- Others
- Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Nigeria
- South Africa
- Others
Bruton's Tyrosine Kinase (BTK) Inhibitors Market Scenario
The global BTK inhibitors market is expected to grow at a significant rate during the forecast period of 2023-2031. The increasing prevalence of B-cell malignancies and autoimmune diseases, rising awareness, and growing investment in research and development activities are the key drivers of the market. North America dominates the market, followed by Europe and Asia Pacific. The leading players in the market are focusing on the development of new drugs and therapies and adopting various strategies to strengthen their position in the market.
North America dominates the BTK inhibitors market, followed by Europe and Asia Pacific. The high prevalence of B-cell malignancies and autoimmune diseases in North America, coupled with favourable reimbursement policies, is driving the growth of the market in the region. Europe is also a significant market for BTK inhibitors, with the presence of key players and increasing investment in research and development activities. The Asia Pacific region is expected to grow at the highest CAGR during the forecast period, owing to the increasing awareness about the diseases and the rising healthcare expenditure in the region.
Key Players in the Global Bruton's Tyrosine Kinase (BTK) Inhibitors Market
The report gives an in-depth analysis of the key players involved in the Bruton's Tyrosine Kinase (BTK) Inhibitors market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:
- BeiGene, Ltd.
- Merck KGaA
- ACEA Biosciences, Inc.
- Principia Biopharma Inc.
- Bristol- Myers Squibb Company
- Adolph Kiefer & Associates, Llc
- Johnson & Johnson Services, Inc
- ACEA Biosciences Inc.
- Aptose Biosciences Inc. (APTO)
- Eternity Bioscience Inc.
- Takeda Pharmaceuticals Industries Ltd.
- Gilead Sciences Inc.
- AbbVie Inc.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
2 Research Methodology
3 Executive Summary
4 Bruton's Tyrosine Kinase (BTK) Inhibitors Overview
4.1 Drug Overview
4.1.1 Pharmacodynamics
4.1.2 Pharmacokinetics
4.1.3 Adverse Events
5 Patient Profile
5.1 Patient Profile Overview
5.2 Patient Psychology and Emotional Impact Factors
5.3 Risk Assessment and Treatment Success Rate
6 Current Scenario Evaluation and Regulatory Framework
6.1 Emerging Therapies and Clinical Trials Synopsis
6.2 Patent Landscape
6.2.1 Patent Overview
6.2.1.1 Patent Status and Expiry
6.2.1.2 Timelines from Drug Development to Commercial Launch
6.2.1.3 New Drug Application
6.2.1.3.1 Documentation and Approval Process
6.3 Cost of Treatment
6.4 Investment Scenarios
6.5 Regulatory Framework
6.5.1 Regulatory Overview
6.5.1.1 US FDA
6.5.1.2 EU EMA
6.5.1.3 INDIA CDSCO
6.5.1.4 JAPAN PMDA
6.5.1.5 Others
7 Challenges and Unmet Need
7.1 Treatment Pathway Challenges
7.2 Compliance and Drop-Out Rate
7.3 Awareness and Prevention Gaps
8 Global Bruton's Tyrosine Kinase (BTK) Inhibitors Market
8.1 Global Bruton's Tyrosine Kinase (BTK) Inhibitors Market Overview
8.2 Global Bruton's Tyrosine Kinase (BTK) Inhibitors Market Analysis
8.2.1 Market Overview
8.2.1.1 Global Bruton's Tyrosine Kinase (BTK) Inhibitors Market Historical Value (2016-2022)
8.2.1.2 Global Bruton's Tyrosine Kinase (BTK) Inhibitors Market Forecast Value (2023-2031)
8.3 Global Bruton's Tyrosine Kinase (BTK) Inhibitors Market by Type
8.3.1 Market Overview
8.3.1.1 First Generation
8.3.1.2 Second Generation
8.4 Global Bruton's Tyrosine Kinase (BTK) Inhibitors Market by Drug
8.4.1 Market Overview
8.4.1.1 Imbruvica
8.4.1.2 Calquence
8.4.1.3 Brukinsa
8.5 Global Bruton's Tyrosine Kinase (BTK) Inhibitors Market by Application
8.5.1 Market Overview
8.5.1.1 Chronic lymphocytic leukemia (CLL)
8.5.1.2 Mantle cell lymphoma (MCL)
8.5.1.3 Waldenstrom's Macroglobulinemia
8.5.1.4 Small Lymphocytic Lymphoma
8.5.1.5 Marginal Zone Lymphoma
8.5.1.6 Others
8.6 Global Bruton's Tyrosine Kinase (BTK) Inhibitors Market by Distribution Channel
8.6.1 Market Overview
8.6.1.1 Hospital Based Pharmacies
8.6.1.2 Online Pharmacies
8.6.1.3 Retail Pharmacies
8.7 Global Bruton's Tyrosine Kinase (BTK) Inhibitors Market by Region
8.7.1 Market Overview
8.7.1.1 North America
8.7.1.2 Europe
8.7.1.3 Asia Pacific
8.7.1.4 Latin America
8.7.1.5 Middle East and Africa
9 North America Bruton's Tyrosine Kinase (BTK) Inhibitors Market
9.1 Market Share by Country
9.2 United States of America
9.2.1 Historical Trend (2016-2022)
9.2.2 Forecast Trend (2023-2031)
9.3 Canada
9.3.1 Historical Trend (2016-2022)
9.3.2 Forecast Trend (2023-2031)
10 Europe Bruton's Tyrosine Kinase (BTK) Inhibitors Market
10.1 Market Share by Country
10.2 United Kingdom
10.2.1 Historical Trend (2016-2022)
10.2.2 Forecast Trend (2023-2031)
10.3 Germany
10.3.1 Historical Trend (2016-2022)
10.3.2 Forecast Trend (2023-2031)
10.4 France
10.4.1 Historical Trend (2016-2022)
10.4.2 Forecast Trend (2023-2031)
10.5 Italy
10.5.1 Historical Trend (2016-2022)
10.5.2 Forecast Trend (2023-2031)
10.6 Others
11 Asia Pacific Bruton's Tyrosine Kinase (BTK) Inhibitors Market
11.1 Market Share by Country
11.2 China
11.2.1 Historical Trend (2016-2022)
11.2.2 Forecast Trend (2023-2031)
11.3 Japan
11.3.1 Historical Trend (2016-2022)
11.3.2 Forecast Trend (2023-2031)
11.4 India
11.4.1 Historical Trend (2016-2022)
11.4.2 Forecast Trend (2023-2031)
11.5 ASEAN
11.5.1 Historical Trend (2016-2022)
11.5.2 Forecast Trend (2023-2031)
11.6 Australia
11.6.1 Historical Trend (2016-2022)
11.6.2 Forecast Trend (2023-2031)
11.7 Others
12 Latin America Bruton's Tyrosine Kinase (BTK) Inhibitors Market
12.1 Market Share by Country
12.2 Brazil
12.2.1 Historical Trend (2016-2022)
12.2.2 Forecast Trend (2023-2031)
12.3 Argentina
12.3.1 Historical Trend (2016-2022)
12.3.2 Forecast Trend (2023-2031)
12.4 Mexico
12.4.1 Historical Trend (2016-2022)
12.4.2 Forecast Trend (2023-2031)
12.5 Others
13 Middle East and Africa Bruton's Tyrosine Kinase (BTK) Inhibitors Market
13.1 Market Share by Country
13.2 Saudi Arabia
13.2.1 Historical Trend (2016-2022)
13.2.2 Forecast Trend (2023-2031)
13.3 United Arab Emirates
13.3.1 Historical Trend (2016-2022)
13.3.2 Forecast Trend (2023-2031)
13.4 Nigeria
13.4.1 Historical Trend (2016-2022)
13.4.2 Forecast Trend (2023-2031)
13.5 South Africa
13.5.1 Historical Trend (2016-2022)
13.5.2 Forecast Trend (2023-2031)
13.6 Others
14 Global Bruton's Tyrosine Kinase (BTK) Inhibitors Market Dynamics
14.1 Market Drivers and Constraints
14.2 SWOT Analysis
14.3 Drug Adoption Parameters
14.4 Porter's Five Forces Model
14.5 Key Demand Indicators
14.6 Key Price Indicators
14.7 Value Chain Analysis
15 Supplier Landscape
15.1 BeiGene, Ltd.
15.1.1 Company Overview
15.1.2 Product Portfolio
15.1.3 Demographic Reach and Achievement
15.1.4 Merger and Acquisitions
15.1.5 Certifications
15.2 Merck KGaA
15.2.1 Company Overview
15.2.2 Product Portfolio
15.2.3 Demographic Reach and Achievement
15.2.4 Merger and Acquisitions
15.2.5 Certifications
15.3 Principia Biopharma Inc.
15.3.1 Company Overview
15.3.2 Product Portfolio
15.3.3 Demographic Reach and Achievement
15.3.4 Merger and Acquisitions
15.3.5 Certifications
15.4 ACEA Biosciences, Inc.
15.4.1 Company Overview
15.4.2 Product Portfolio
15.4.3 Demographic Reach and Achievement
15.4.4 Merger and Acquisitions
15.4.5 Certifications
15.5 Bristol- Myers Squibb Company
15.5.1 Company Overview
15.5.2 Product Portfolio
15.5.3 Demographic Reach and Achievement
15.5.4 Merger and Acquisitions
15.5.5 Certifications
15.6 Adolph Kiefer & Associates, Llc
15.6.1 Company Overview
15.6.2 Product Portfolio
15.6.3 Demographic Reach and Achievement
15.6.4 Merger and Acquisitions
15.6.5 Certifications
15.7 Johnson & Johnson Services, Inc
15.7.1 Company Overview
15.7.2 Product Portfolio
15.7.3 Demographic Reach and Achievement
15.7.4 Merger and Acquisitions
15.7.5 Certifications
15.8 ACEA Biosciences Inc.
15.8.1 Company Overview
15.8.2 Product Portfolio
15.8.3 Demographic Reach and Achievement
15.8.4 Merger and Acquisitions
15.8.5 Certifications
15.9 Aptose Biosciences Inc. (APTO)
15.9.1 Company Overview
15.9.2 Product Portfolio
15.9.3 Demographic Reach and Achievement
15.9.4 Merger and Acquisitions
15.9.5 Certifications
15.10 Eternity Bioscience Inc.
15.10.1 Company Overview
15.10.2 Product Portfolio
15.10.3 Demographic Reach and Achievement
15.10.4 Merger and Acquisitions
15.10.5 Certifications
15.11 Takeda Pharmaceuticals Industries Ltd.
15.11.1 Company Overview
15.11.2 Product Portfolio
15.11.3 Demographic Reach and Achievement
15.11.4 Merger and Acquisitions
15.11.5 Certifications
15.12 Gilead Sciences Inc.
15.12.1 Company Overview
15.12.2 Product Portfolio
15.12.3 Demographic Reach and Achievement
15.12.4 Merger and Acquisitions
15.12.5 Certifications
15.13 AbbVie Inc.
15.13.1 Company Overview
15.13.2 Product Portfolio
15.13.3 Demographic Reach and Achievement
15.13.4 Merger and Acquisitions
15.13.5 Certifications
16 Pricing Models and Strategies (Additional Insight)
16.1 Cost Model
16.1.1 Manufacturing Cost Analysis
16.1.2 Procurement Cost Analysis
16.2 Pricing Strategies
16.2.1 Competitor Pricing Analysis
16.2.2 Key Assessment of Product Attributes
16.2.3 Pricing Benchmark
17 Global Bruton's Tyrosine Kinase (BTK) Inhibitor Market- Distribution Model (Additional Insight)
17.1 Overview
17.2 Potential Distributors
17.3 Key Parameters for Distribution Partner Assessment
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security